nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—DRD5—eyelid—leprosy	0.135	0.267	CbGeAlD
L-DOPA—SLC7A8—skin epidermis—leprosy	0.0508	0.1	CbGeAlD
L-DOPA—PSIP1—Menadione—Thalidomide—leprosy	0.0418	1	CbGdCrCtD
L-DOPA—DDC—nerve—leprosy	0.0375	0.0739	CbGeAlD
L-DOPA—DRD1—nerve—leprosy	0.0275	0.0543	CbGeAlD
L-DOPA—PSIP1—eye—leprosy	0.0274	0.0542	CbGeAlD
L-DOPA—Dementia—Thalidomide—leprosy	0.0185	0.0409	CcSEcCtD
L-DOPA—DRD2—nerve—leprosy	0.0163	0.0321	CbGeAlD
L-DOPA—SLC7A8—skin of body—leprosy	0.0157	0.0311	CbGeAlD
L-DOPA—White blood cell count decreased—Thalidomide—leprosy	0.0152	0.0338	CcSEcCtD
L-DOPA—PSIP1—testis—leprosy	0.0151	0.0297	CbGeAlD
L-DOPA—PSIP1—nervous system—leprosy	0.0148	0.0292	CbGeAlD
L-DOPA—SLC7A5—eye—leprosy	0.014	0.0277	CbGeAlD
L-DOPA—DRD4—testis—leprosy	0.0125	0.0247	CbGeAlD
L-DOPA—Serum creatinine increased—Thalidomide—leprosy	0.0123	0.0273	CcSEcCtD
L-DOPA—SLC7A5—skin of body—leprosy	0.0122	0.0241	CbGeAlD
L-DOPA—SLC7A8—tendon—leprosy	0.012	0.0236	CbGeAlD
L-DOPA—Psychotic disorder—Dapsone—leprosy	0.0105	0.0233	CcSEcCtD
L-DOPA—SLC7A8—testis—leprosy	0.00992	0.0196	CbGeAlD
L-DOPA—SLC7A8—nervous system—leprosy	0.00974	0.0192	CbGeAlD
L-DOPA—Nasopharyngitis—Dapsone—leprosy	0.00961	0.0213	CcSEcCtD
L-DOPA—SLC7A5—tendon—leprosy	0.00928	0.0183	CbGeAlD
L-DOPA—Numbness—Thalidomide—leprosy	0.00915	0.0203	CcSEcCtD
L-DOPA—Blood disorder—Thalidomide—leprosy	0.00908	0.0201	CcSEcCtD
L-DOPA—Sensory loss—Thalidomide—leprosy	0.00875	0.0194	CcSEcCtD
L-DOPA—DRD3—nervous system—leprosy	0.00864	0.0171	CbGeAlD
L-DOPA—DDC—testis—leprosy	0.00858	0.0169	CbGeAlD
L-DOPA—DDC—nervous system—leprosy	0.00842	0.0166	CbGeAlD
L-DOPA—Neuropathy peripheral—Dapsone—leprosy	0.00812	0.018	CcSEcCtD
L-DOPA—DRD5—nervous system—leprosy	0.0081	0.016	CbGeAlD
L-DOPA—Dyskinesia—Thalidomide—leprosy	0.00807	0.0179	CcSEcCtD
L-DOPA—Gait disturbance—Thalidomide—leprosy	0.00777	0.0172	CcSEcCtD
L-DOPA—SLC7A5—testis—leprosy	0.00769	0.0152	CbGeAlD
L-DOPA—SLC7A5—nervous system—leprosy	0.00755	0.0149	CbGeAlD
L-DOPA—Blood urea increased—Thalidomide—leprosy	0.00716	0.0159	CcSEcCtD
L-DOPA—SLC16A10—tendon—leprosy	0.00711	0.014	CbGeAlD
L-DOPA—DRD2—eye—leprosy	0.00679	0.0134	CbGeAlD
L-DOPA—Hyperkinesia—Thalidomide—leprosy	0.00661	0.0146	CcSEcCtD
L-DOPA—Euphoric mood—Thalidomide—leprosy	0.00651	0.0144	CcSEcCtD
L-DOPA—DRD1—nervous system—leprosy	0.00619	0.0122	CbGeAlD
L-DOPA—Vascular purpura—Thalidomide—leprosy	0.00615	0.0136	CcSEcCtD
L-DOPA—Vision blurred—Dapsone—leprosy	0.0061	0.0135	CcSEcCtD
L-DOPA—SLC16A10—testis—leprosy	0.00589	0.0116	CbGeAlD
L-DOPA—Dermatitis bullous—Thalidomide—leprosy	0.00576	0.0128	CcSEcCtD
L-DOPA—Purpura—Thalidomide—leprosy	0.00571	0.0126	CcSEcCtD
L-DOPA—Cough—Dapsone—leprosy	0.00565	0.0125	CcSEcCtD
L-DOPA—Diplopia—Thalidomide—leprosy	0.0055	0.0122	CcSEcCtD
L-DOPA—Pain in extremity—Thalidomide—leprosy	0.0055	0.0122	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.0055	0.0122	CcSEcCtD
L-DOPA—Disturbance in sexual arousal—Thalidomide—leprosy	0.00546	0.0121	CcSEcCtD
L-DOPA—Psychotic disorder—Thalidomide—leprosy	0.00538	0.0119	CcSEcCtD
L-DOPA—Ataxia—Thalidomide—leprosy	0.00518	0.0115	CcSEcCtD
L-DOPA—Blood creatinine increased—Thalidomide—leprosy	0.00516	0.0114	CcSEcCtD
L-DOPA—Orthostatic hypotension—Thalidomide—leprosy	0.00503	0.0111	CcSEcCtD
L-DOPA—Cramp muscle—Thalidomide—leprosy	0.00496	0.011	CcSEcCtD
L-DOPA—Insomnia—Dapsone—leprosy	0.00478	0.0106	CcSEcCtD
L-DOPA—Dysphagia—Thalidomide—leprosy	0.00476	0.0105	CcSEcCtD
L-DOPA—Angina pectoris—Thalidomide—leprosy	0.00463	0.0103	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Thalidomide—leprosy	0.00442	0.00979	CcSEcCtD
L-DOPA—Pollakiuria—Thalidomide—leprosy	0.00439	0.00973	CcSEcCtD
L-DOPA—Weight increased—Thalidomide—leprosy	0.00433	0.00959	CcSEcCtD
L-DOPA—Gastrointestinal pain—Dapsone—leprosy	0.00432	0.00957	CcSEcCtD
L-DOPA—Weight decreased—Thalidomide—leprosy	0.0043	0.00953	CcSEcCtD
L-DOPA—Depression—Thalidomide—leprosy	0.00423	0.00937	CcSEcCtD
L-DOPA—Acute coronary syndrome—Thalidomide—leprosy	0.00418	0.00926	CcSEcCtD
L-DOPA—Abdominal pain—Dapsone—leprosy	0.00418	0.00925	CcSEcCtD
L-DOPA—Myocardial infarction—Thalidomide—leprosy	0.00416	0.00921	CcSEcCtD
L-DOPA—Neuropathy peripheral—Thalidomide—leprosy	0.00416	0.00921	CcSEcCtD
L-DOPA—Agranulocytosis—Thalidomide—leprosy	0.00396	0.00877	CcSEcCtD
L-DOPA—Rhinitis—Thalidomide—leprosy	0.00382	0.00845	CcSEcCtD
L-DOPA—Hypoaesthesia—Thalidomide—leprosy	0.00379	0.00839	CcSEcCtD
L-DOPA—Urinary tract disorder—Thalidomide—leprosy	0.00376	0.00833	CcSEcCtD
L-DOPA—Urethral disorder—Thalidomide—leprosy	0.00373	0.00827	CcSEcCtD
L-DOPA—DRD2—testis—leprosy	0.00373	0.00735	CbGeAlD
L-DOPA—DRD2—nervous system—leprosy	0.00366	0.00722	CbGeAlD
L-DOPA—Arrhythmia—Thalidomide—leprosy	0.0034	0.00753	CcSEcCtD
L-DOPA—Alopecia—Thalidomide—leprosy	0.00336	0.00745	CcSEcCtD
L-DOPA—Vomiting—Dapsone—leprosy	0.00336	0.00744	CcSEcCtD
L-DOPA—Mental disorder—Thalidomide—leprosy	0.00334	0.00739	CcSEcCtD
L-DOPA—Headache—Dapsone—leprosy	0.00331	0.00733	CcSEcCtD
L-DOPA—Flatulence—Thalidomide—leprosy	0.00327	0.00723	CcSEcCtD
L-DOPA—Tension—Thalidomide—leprosy	0.00325	0.0072	CcSEcCtD
L-DOPA—Dysgeusia—Thalidomide—leprosy	0.00325	0.00719	CcSEcCtD
L-DOPA—Nervousness—Thalidomide—leprosy	0.00322	0.00713	CcSEcCtD
L-DOPA—Back pain—Thalidomide—leprosy	0.00321	0.0071	CcSEcCtD
L-DOPA—Muscle spasms—Thalidomide—leprosy	0.00319	0.00706	CcSEcCtD
L-DOPA—Nausea—Dapsone—leprosy	0.00314	0.00695	CcSEcCtD
L-DOPA—Vision blurred—Thalidomide—leprosy	0.00312	0.00692	CcSEcCtD
L-DOPA—Tremor—Thalidomide—leprosy	0.00311	0.00688	CcSEcCtD
L-DOPA—Ill-defined disorder—Thalidomide—leprosy	0.00308	0.00681	CcSEcCtD
L-DOPA—Anaemia—Thalidomide—leprosy	0.00306	0.00679	CcSEcCtD
L-DOPA—Agitation—Thalidomide—leprosy	0.00305	0.00675	CcSEcCtD
L-DOPA—Angioedema—Thalidomide—leprosy	0.00303	0.00671	CcSEcCtD
L-DOPA—Malaise—Thalidomide—leprosy	0.00299	0.00662	CcSEcCtD
L-DOPA—Syncope—Thalidomide—leprosy	0.00297	0.00658	CcSEcCtD
L-DOPA—Leukopenia—Thalidomide—leprosy	0.00297	0.00657	CcSEcCtD
L-DOPA—Palpitations—Thalidomide—leprosy	0.00293	0.00649	CcSEcCtD
L-DOPA—Loss of consciousness—Thalidomide—leprosy	0.00291	0.00645	CcSEcCtD
L-DOPA—Cough—Thalidomide—leprosy	0.00289	0.00641	CcSEcCtD
L-DOPA—Convulsion—Thalidomide—leprosy	0.00287	0.00636	CcSEcCtD
L-DOPA—Hypertension—Thalidomide—leprosy	0.00286	0.00634	CcSEcCtD
L-DOPA—Chest pain—Thalidomide—leprosy	0.00282	0.00625	CcSEcCtD
L-DOPA—Anxiety—Thalidomide—leprosy	0.00281	0.00623	CcSEcCtD
L-DOPA—Discomfort—Thalidomide—leprosy	0.00279	0.00618	CcSEcCtD
L-DOPA—Dry mouth—Thalidomide—leprosy	0.00276	0.00611	CcSEcCtD
L-DOPA—Confusional state—Thalidomide—leprosy	0.00273	0.00604	CcSEcCtD
L-DOPA—Oedema—Thalidomide—leprosy	0.00271	0.00599	CcSEcCtD
L-DOPA—Shock—Thalidomide—leprosy	0.00266	0.00589	CcSEcCtD
L-DOPA—Thrombocytopenia—Thalidomide—leprosy	0.00265	0.00587	CcSEcCtD
L-DOPA—Hyperhidrosis—Thalidomide—leprosy	0.00262	0.00579	CcSEcCtD
L-DOPA—Anorexia—Thalidomide—leprosy	0.00258	0.00571	CcSEcCtD
L-DOPA—Hypotension—Thalidomide—leprosy	0.00253	0.0056	CcSEcCtD
L-DOPA—Insomnia—Thalidomide—leprosy	0.00245	0.00542	CcSEcCtD
L-DOPA—Paraesthesia—Thalidomide—leprosy	0.00243	0.00538	CcSEcCtD
L-DOPA—Dyspnoea—Thalidomide—leprosy	0.00241	0.00534	CcSEcCtD
L-DOPA—Somnolence—Thalidomide—leprosy	0.0024	0.00533	CcSEcCtD
L-DOPA—Dyspepsia—Thalidomide—leprosy	0.00238	0.00527	CcSEcCtD
L-DOPA—Decreased appetite—Thalidomide—leprosy	0.00235	0.00521	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Thalidomide—leprosy	0.00234	0.00517	CcSEcCtD
L-DOPA—Fatigue—Thalidomide—leprosy	0.00233	0.00517	CcSEcCtD
L-DOPA—Constipation—Thalidomide—leprosy	0.00231	0.00512	CcSEcCtD
L-DOPA—Pain—Thalidomide—leprosy	0.00231	0.00512	CcSEcCtD
L-DOPA—CYP2D6—testis—leprosy	0.00224	0.00442	CbGeAlD
L-DOPA—Feeling abnormal—Thalidomide—leprosy	0.00223	0.00494	CcSEcCtD
L-DOPA—Gastrointestinal pain—Thalidomide—leprosy	0.00221	0.0049	CcSEcCtD
L-DOPA—CYP2D6—nervous system—leprosy	0.0022	0.00434	CbGeAlD
L-DOPA—Urticaria—Thalidomide—leprosy	0.00215	0.00476	CcSEcCtD
L-DOPA—Abdominal pain—Thalidomide—leprosy	0.00214	0.00474	CcSEcCtD
L-DOPA—Hypersensitivity—Thalidomide—leprosy	0.00199	0.00441	CcSEcCtD
L-DOPA—Asthenia—Thalidomide—leprosy	0.00194	0.0043	CcSEcCtD
L-DOPA—Pruritus—Thalidomide—leprosy	0.00191	0.00424	CcSEcCtD
L-DOPA—Diarrhoea—Thalidomide—leprosy	0.00185	0.0041	CcSEcCtD
L-DOPA—Dizziness—Thalidomide—leprosy	0.00179	0.00396	CcSEcCtD
L-DOPA—Vomiting—Thalidomide—leprosy	0.00172	0.00381	CcSEcCtD
L-DOPA—Rash—Thalidomide—leprosy	0.00171	0.00378	CcSEcCtD
L-DOPA—Dermatitis—Thalidomide—leprosy	0.0017	0.00377	CcSEcCtD
L-DOPA—Headache—Thalidomide—leprosy	0.00169	0.00375	CcSEcCtD
L-DOPA—Nausea—Thalidomide—leprosy	0.00161	0.00356	CcSEcCtD
